Idexx Laboratories Financial Model
Medical Devices Company Financials Example (Free Excel Download)
IDEXX Laboratories, Inc. is a global leader in veterinary diagnostics, veterinary practice software, and water microbiology testing.
professionals from Deloitte
Used by professionals from
About this model
This model provides a comprehensive 3-statement financial forecast and discounted cash flow valuation to determine the intrinsic equity value of IDEXX Laboratories, enabling an equity research analyst to assess whether the stock's premium valuation multiple is justified by its highly recurring diagnostic revenue and margin expansion trajectory.
IDEXX Laboratories, Inc. is a global leader in veterinary diagnostics, veterinary practice software, and water microbiology testing. The company operates a classic "razor and razorblade" business model, placing diagnostic instruments in veterinary clinics to drive highly profitable, recurring consumable and reference laboratory testing revenue.
Business segments:
- Companion Animal Group (CAG): Approximately 91% of total revenue.
- Water: Approximately 4% of total revenue.
- Livestock, Poultry and Dairy (LPD): Approximately 3% of total revenue.
- Other: Approximately 2% of total revenue.
Key geographies:
- United States: Approximately 65% of revenue.
- International: Approximately 35% of revenue.
The company operates an asset-light, innovation-driven business model with significant pricing power and high switching costs for veterinary practices. Its competitive position is dominant, holding the number one market share globally in companion animal diagnostics, competing primarily against Zoetis, Heska (Mars), and Antech (Mars). Recent major events include the launch of the IDEXX inVue Dx cellular analyser, the IDEXX Cancer Dx panel, and the resolution of a discrete litigation matter in 2024/2025 which temporarily impacted reported operating margins.
The downloadable Idexx Laboratories financial model includes SEC-sourced historical financials, forecast assumptions, core operating schedules, and valuation outputs in an Excel workbook built for review and scenario analysis.
A turnkey financial model
Live formulas, no hardcoded values
Outputs are driven by live formulas, so the workbook updates from its assumptions instead of relying on hardcoded results.
All assumptions in one tab
Inputs are clearly marked in the Assumptions tab and separated from calculations, making it clear what to change and what to leave intact.
Statements always balancing
For integrated-statement models, the balance sheet, cash flow, and supporting schedules tie through properly.
Distinct schedules for clarity
Debt, working capital, taxes, and cash flow can get messy quickly. We group calculations in clear schedules, not across disconnected tabs.
No hidden macros or external links
There are no unexplained external workbook links or macros to undermine auditability or portability.
Changes flow through the model
Update a key driver and see the impact carry through the forecast, financing, and return outputs. We never use hardcoded numbers in formulas.
Historicals & AssumptionsIdexx Laboratories financial modelCompany, Historicals & Assumptions used
Source: SEC EDGAR · values in USD
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $3.22B | $3.37B | $3.66B | $3.90B | $4.30B |
| Gross profit | $1.89B | $2.00B | $2.19B | $2.38B | $2.66B |
| Operating income | $932.0M | $898.8M | $1.10B | $1.13B | $1.36B |
| Net income | $744.8M | $679.1M | $845.0M | $887.9M | $1.06B |
Forecast assumptions
Defaults used in the downloadable model. Forecast horizon: FY2026–FY2030.
See 8 moreSee less
How to build a detailed financial model for Idexx Laboratories
A complete walkthrough of every driver, margin, working-capital input, and capital-allocation assumption used in the downloadable model.
Revenue Deep Dive
Companion Animal Group (CAG) - Diagnostics Recurring
- Segment name: CAG Diagnostics recurring revenue (includes IDEXX VetLab consumables, reference laboratory services, and rapid assay products).
- Revenue driver formula: Premium Instrument Installed Base x Average Consumable Revenue per Instrument + Reference Lab Volume x Average Price per Test.
- Historical growth rate: 8% to 12% organic CAGR.
- Key growth levers and headwinds: Driven by growth in clinical visits, increased diagnostic frequency per visit, and net price realisation. Headwinds include macroeconomic pressures on veterinary visit volumes and veterinary clinic staffing shortages.
- Pricing dynamics: Strong pricing power, typically achieving 4% to 5% annual net price realisation.
- Revenue recognition notes: Consumables recognised upon shipment or delivery; reference lab services recognised when test results are provided.
- Seasonality: Modestly higher in the spring and summer months (Q2 and Q3) due to higher incidence of vector-borne diseases (e.g., tick and heartworm testing).
Companion Animal Group (CAG) - Diagnostics Capital
- Segment name: CAG Diagnostics capital – instruments.
- Revenue driver formula: Number of Instruments Placed x Average Selling Price.
- Historical growth rate: 4% to 8% CAGR, highly dependent on new product launch cycles.
- Key growth levers and headwinds: Driven by new clinic openings, competitive takeaways, and upgrades to newer technologies (e.g., inVue Dx). Headwinds include high interest rates deterring clinic capital expenditure.
- Pricing dynamics: Often discounted or placed via customer rebate programmes (e.g., IDEXX Instrument Marketing Programmes) in exchange for long-term consumable purchase commitments.
- Revenue recognition notes: Recognised upon installation and acceptance.
- Seasonality: Often stronger in Q4 as clinics utilise year-end tax incentives for capital equipment purchases.
Companion Animal Group (CAG) - Veterinary Software and Diagnostic Imaging
- Segment name: Veterinary software, services and diagnostic imaging systems.
- Revenue driver formula: Software Subscriptions x ARPU + Imaging Systems Placed x ASP.
- Historical growth rate: 9% to 12% CAGR.
- Key growth levers and headwinds: Transition of clinics to cloud-based practice information management systems (e.g., ezyVet) and integration with IDEXX diagnostic workflows.
- Pricing dynamics: Subscription-based pricing for cloud software; upfront capital sales for imaging equipment.
- Revenue recognition notes: Software-as-a-Service (SaaS) subscriptions are recognised ratably over the contract term.
- Seasonality: Relatively smooth due to the recurring SaaS revenue profile.
Water
- Segment name: Water.
- Revenue driver formula: Testing Volume x Price per Test.
- Historical growth rate: 8% to 10% CAGR.
- Key growth levers and headwinds: Regulatory requirements for water testing and global population growth.
- Pricing dynamics: Regulated and highly contractual.
- Revenue recognition notes: Recognised upon shipment of testing kits.
- Seasonality: Stronger in Q2 and Q3 due to increased recreational water testing in the Northern Hemisphere.
Livestock, Poultry and Dairy (LPD)
- Segment name: Livestock, Poultry and Dairy.
- Revenue driver formula: Herd/Flock Testing Volume x Price per Test.
- Historical growth rate: 2% to 5% CAGR.
- Key growth levers and headwinds: Disease eradication programmes and macroeconomic conditions in the agricultural sector. African Swine Fever outbreaks historically caused volatility.
- Pricing dynamics: Competitive, often tender-based for government eradication programmes.
- Revenue recognition notes: Recognised upon shipment.
- Seasonality: Varies based on regional disease outbreaks and government testing schedules.
Cost Structure
Variable Costs / COGS
- Line-by-line breakdown: Manufacturing materials, direct labour, freight, reference laboratory operations (personnel, supplies, courier costs), and software hosting costs.
- Gross margin range: 59.0% to 61.5% over the last 5 years (60.3% in Q4 2025).
- Key input costs and commodity exposures: Electronic components for instruments, biological materials for assays, and fuel/logistics costs for reference lab couriers.
- How COGS scales with revenue: High operating leverage. Consumables and software have very high incremental gross margins, while reference labs require step-function investments in capacity and courier routes.
Operating Expenses
- R&D: Typically 5.0% to 6.0% of revenue. Covers development of new assays, cellular analysers, and software engineering. Software development costs are partially capitalised.
- SG&A: Typically 23.0% to 25.0% of revenue. Heavily weighted towards the direct veterinary sales force, marketing, and corporate administrative functions.
- Depreciation & Amortisation: Typically 3.0% to 4.0% of revenue, split primarily between tangible reference lab equipment and capitalised software.
- Stock-Based Compensation: Typically 1.5% to 2.0% of revenue.
- Restructuring / one-time charges: Infrequent, though the company recorded a significant discrete litigation expense accrual in 2024 ($61.5 million) which was partially reversed in 2025.
Margin Profile
- Gross margin: 59.0% to 61.5%.
- EBITDA margin: 32.0% to 35.0%.
- Operating margin: 28.0% to 31.8% (projected full-year 2025 was approximately 31.6%).
- Net margin: 22.0% to 24.0%.
- Margin trend: Expanding. The company targets 50 to 100 basis points of comparable operating margin expansion annually, driven by mix shift towards high-margin CAG Diagnostics recurring revenue and reference lab productivity initiatives.
Balance Sheet Structure
- Total assets: Approximately $3.3 billion.
- Key asset categories: Inventory (instruments and consumable safety stock), Property and Equipment (reference labs), and Goodwill/Intangibles.
- Goodwill & intangibles as % of total assets: Approximately 15% to 20%, reflecting a history of bolt-on software acquisitions (e.g., ezyVet).
- Working capital profile:
- Days Sales Outstanding (DSO): 35 to 45 days.
- Days Inventory Outstanding (DIO): 90 to 110 days (high inventory levels maintained to ensure diagnostic availability).
- Days Payable Outstanding (DPO): 30 to 40 days.
- Net working capital as % of revenue: Typically 8% to 12%.
- Is working capital positive or negative? Positive. The company requires moderate working capital investment to fund inventory growth.
- PP&E: Consists of reference laboratory facilities, manufacturing equipment, and internal-use software. Useful lives range from 3 to 10 years for equipment and up to 30 years for buildings.
- Right-of-use assets / operating leases: Material, representing leased reference lab spaces and corporate offices (approximately $150 million to $200 million).
Capital Expenditure & Investment
- Capex as % of revenue: 3.5% to 5.0%.
- Maintenance capex vs. growth capex: Approximately 40% maintenance, 60% growth (expansion of global reference lab network and manufacturing capacity).
- Major capex programmes underway or planned: Continuous expansion of the global reference laboratory footprint and investments in automated lab technologies.
- Capitalised software / development costs: Material. The company capitalises costs related to internal-use software and customer-facing SaaS platforms.
- M&A pattern: Bolt-on acquirer. Focuses on veterinary software (e.g., ezyVet, Animana) and regional reference laboratories to expand geographic reach.
- Typical acquisition multiple paid: High multiples (often 5x to 10x revenue) for high-growth SaaS assets, though absolute deal sizes are usually small (under $200 million).
Debt & Capital Structure
- Total debt: Approximately $700 million to $900 million.
- Debt/EBITDA ratio: Very low, typically 0.5x to 1.0x.
- Credit rating: Investment grade profile, though often unrated by major agencies due to low reliance on public debt markets.
- Key debt instruments: $1 billion unsecured revolving credit facility and term loans.
- Maturity profile: Weighted towards the end of the 5-year credit facility term (renewed in 2021/2024).
- Interest rate profile: Primarily floating rate based on SOFR, though the company occasionally uses interest rate swaps.
- Covenants: Maximum consolidated leverage ratio of 3.5x. The company operates well below this limit.
- Share repurchase programme: Highly active. The company routinely allocates the majority of its free cash flow to share repurchases, reducing share count by 1% to 2% annually.
- Dividend policy: The company does not pay a dividend, preferring to return capital via share repurchases.
Cash Flow Characteristics
- Operating cash flow conversion: 105% to 115% of Net Income.
- Free cash flow margin: 18% to 22% of Revenue (FCF is typically 95% to 100% of Net Income).
- Major non-cash items that bridge net income to OCF: Depreciation and amortisation, stock-based compensation (significant tax benefits), and deferred tax provisions.
- Working capital cash flow impact: Moderate use of cash as inventory and receivables grow alongside revenue.
- Capex intensity: Low to moderate (under 5% of revenue), allowing for massive free cash flow generation.
- Cash tax rate vs. GAAP effective tax rate: Cash taxes are often lower than the GAAP effective tax rate (typically 20% to 22%) due to excess tax benefits from stock-based compensation.
Sheet Structure
- Assumptions: Hardcoded drivers for macroeconomic inputs, segment revenue growth, pricing, margins, working capital days, capex, and capital structure.
- Scenarios: Scenario manager (Base, Bull, Bear) toggling key drivers like CAG recurring volume growth, net price realisation, and operating margin expansion.
- Revenue Build: Detailed build for CAG (Recurring, Capital, Software), Water, and LPD. Calculates volume and price impacts where applicable.
- Income Statement: Consolidated P&L mirroring the 10-K, from Revenue down to Net Income and EPS. Includes share count schedule.
- Balance Sheet: Standard assets, liabilities, and equity. Includes detailed working capital schedules.
- Cash Flow Statement: Indirect method starting from Net Income, adjusting for non-cash items, working capital changes, capex, debt issuance/repayment, and share repurchases.
- Debt Schedule: Tranches of the revolving credit facility and term loans, calculating interest expense and tracking covenant headroom.
- PP&E and Intangibles: Waterfall schedules for capex, depreciation, software capitalisation, and amortisation.
- Working Capital: Schedule calculating receivables, inventory, and payables based on DSO, DIO, and DPO assumptions.
- DCF Valuation: Unlevered free cash flow calculation, WACC build, terminal value (Gordon Growth), and implied share price.
- Outputs & Charts: Summary dashboard of key metrics (Revenue growth, EPS, FCF margin, ROIC) for presentation.
Key Financial Relationships
- CAG Diagnostics Recurring Revenue = Prior Year CAG Diagnostics Recurring Revenue x (1 + Volume Growth Rate + Net Price Realisation Rate).
- CAG Diagnostics Capital Revenue = Prior Year CAG Diagnostics Capital Revenue x (1 + Instrument Placement Growth Rate).
- Total CAG Revenue = CAG Diagnostics Recurring Revenue + CAG Diagnostics Capital Revenue + Veterinary Software and Diagnostic Imaging Revenue.
- Consolidated Revenue = Total CAG Revenue + Water Revenue + LPD Revenue + Other Revenue.
- Gross Profit = Consolidated Revenue - Cost of Revenue (calculated via Gross Margin % assumption).
- Operating Expenses = Sales and Marketing + General and Administrative + Research and Development.
- Operating Income = Gross Profit - Operating Expenses.
- Accounts Receivable = (Consolidated Revenue / 365) x DSO.
- Inventory = (Cost of Revenue / 365) x DIO.
- Accounts Payable = (Cost of Revenue / 365) x DPO.
- Free Cash Flow = Cash from Operations - Capital Expenditures.
- Basic Shares Outstanding = Prior Period Shares - (Share Repurchases / Average Share Price).
- Diluted EPS = Net Income / Diluted Shares Outstanding.
Cross-Sheet Dependencies
- The Assumptions sheet dictates the growth rates and margin profiles used in the Revenue Build and Income Statement.
- The Revenue Build feeds the top line of the Income Statement and drives the Accounts Receivable calculation in the Working Capital sheet.
- The Income Statement generates Net Income, which is the starting point for the Cash Flow Statement and feeds Retained Earnings on the Balance Sheet.
- The Working Capital sheet calculates changes in operating assets and liabilities, which feed the operating section of the Cash Flow Statement.
- The PP&E and Intangibles sheet calculates Depreciation and Amortisation, which feeds the Income Statement (operating expenses) and the Cash Flow Statement (non-cash add-back).
- The Debt Schedule calculates interest expense, which feeds the Income Statement. *Circularity risk:* Interest expense lowers Net Income, which lowers cash flow, which dictates debt paydown/drawdown, which changes the debt balance, which changes interest expense. A circularity breaker (toggle) must be included.
- The Cash Flow Statement determines the ending cash balance and debt requirements, feeding the Balance Sheet.
- The DCF Valuation pulls Unlevered Free Cash Flow from the Cash Flow Statement and tax data from the Income Statement.
Sign Convention
- Revenue and Assets: Positive.
- Expenses and Liabilities: Positive in their respective schedules, but subtracted in aggregation formulas (e.g., Gross Profit = Revenue - COGS).
- Cash Flow Statement: Cash inflows are positive; cash outflows (including capex, share repurchases, and debt repayments) are negative.
- Contra-accounts: Accumulated depreciation and treasury stock are represented as negative numbers on the Balance Sheet.
Things Most Likely to Go Wrong
- Ignoring the razor/razorblade dynamic: Modelling instrument revenue growth without a corresponding flow-through to recurring consumable revenue will severely understate long-term margins.
- Mismodelling the litigation accrual: The company recorded a $61.5 million discrete litigation expense in 2024 and reversed a portion in 2025. The model must normalise historical operating margins to exclude this noise for accurate forecasting.
- Foreign exchange volatility: IDEXX generates ~35% of revenue internationally. The model must separate organic constant-currency growth from reported growth, as FX swings can distort underlying volume trends.
- Underestimating share repurchases: IDEXX uses almost all its free cash flow to buy back stock. Failing to model continuous share count reduction will result in understated EPS.
- Capitalised software costs: The company capitalises significant internal-use software costs. Treating all R&D as an immediate expense will misalign operating cash flow and free cash flow metrics.
- Tax benefit from stock-based compensation: IDEXX consistently reports a lower effective tax rate than the statutory rate due to excess tax benefits from equity awards. Hardcoding a flat 21% or 25% tax rate will understate net income.
- Working capital drag: Because IDEXX must maintain high inventory levels to ensure 100% diagnostic availability, rapid revenue growth consumes cash via inventory build. The model must link inventory strictly to COGS via DIO.
- Margin expansion limits: While IDEXX targets 50-100 bps of annual margin expansion, modelling this indefinitely will eventually result in unrealistic margins. The model should cap terminal operating margins around 35%.
Validation Checks
- "Gross margin should be in the 59.0% to 62.0% range based on the last 5 years; flag if outside this band."
- "Operating margin should demonstrate 50 to 100 basis points of annual expansion until reaching a terminal cap of 35.0%."
- "CAG Diagnostics recurring revenue must account for >75% of total consolidated revenue."
- "Free Cash Flow conversion (FCF / Net Income) should be between 90% and 105%."
- "Capex as a % of revenue should remain between 3.5% and 5.0%."
- "Debt/EBITDA should remain below 1.5x, well within the 3.5x covenant limit."
- "Balance sheet must balance: Total Assets = Total Liabilities + Equity in every period."
- "Effective tax rate should remain between 20.0% and 22.0%."
Key Assumptions (Default Values)
| Assumption | Default Value | Unit | Rationale |
|---|---|---|---|
| CAG Diagnostics Recurring Revenue Growth | 8.5 | % | Midpoint of management's 2025 organic growth outlook (7.5% - 9.5%). |
| CAG Diagnostics Capital Revenue Growth | 5.0 | % | Historical average, reflecting steady instrument placements. |
| Vet Software & Diagnostic Imaging Growth | 9.0 | % | Continued adoption of cloud-based practice management systems. |
| Water Revenue Growth | 10.0 | % | Based on 2025 reported organic growth rates. |
| LPD Revenue Growth | 4.0 | % | Historical average for the agricultural testing segment. |
| Gross Margin | 61.0 | % | Aligns with 2025 actuals and reflects ongoing mix shift to high-margin recurring revenue. |
| R&D as % of Revenue | 5.5 | % | Consistent with historical investment levels in new assays and software. |
| SG&A as % of Revenue | 24.0 | % | Historical average, reflecting direct sales force investments. |
| Effective Tax Rate | 21.0 | % | Historical average, inclusive of stock-based compensation tax benefits. |
| Days Sales Outstanding (DSO) | 40 | Days | Calculated from recent balance sheet averages. |
| Days Inventory Outstanding (DIO) | 100 | Days | Calculated from recent balance sheet averages. |
| Days Payable Outstanding (DPO) | 35 | Days | Calculated from recent balance sheet averages. |
| Capex as % of Revenue | 4.0 | % | Aligns with management guidance for reference lab expansion. |
| Annual Share Repurchases | 500 | $ Millions | Estimated based on historical free cash flow allocation. |
| Average Interest Rate on Debt | 5.5 | % | Estimated based on current SOFR plus applicable margin. |
| WACC | 8.0 | % | Standard discount rate for a high-quality, low-beta healthcare equipment company. |
| Terminal Growth Rate | 3.0 | % | Reflects long-term structural growth in the pet healthcare market. |
Data Sources & Benchmarks
- Filings: SEC EDGAR database for IDEXX Laboratories (IDXX) 10-K, 10-Q, and 8-K filings.
- Investor Relations: IDEXX Investor Relations website for earnings presentations, Investor Day slides (August 2025), and financial outlook summaries.
- Key Peers for Benchmarking: Zoetis (ZTS), Heska/Mars (private, but historical data available), Neogen (NEOG), and Antech/Mars.
- Industry Data Sources: American Veterinary Medical Association (AVMA) for pet ownership trends, IDEXX's own Veterinary Value Index (VVI) for clinical visit data.
- Consensus Estimates: FactSet or Bloomberg for forward-looking revenue and EPS consensus to validate model outputs.
Sources
- IDEXX Laboratories, Inc. Form 10-K for the fiscal year ended December 31, 2025 (filed February 2026 via SEC EDGAR).
- IDEXX Laboratories Q4 2025 Earnings Release and Presentation (February 2026).
- IDEXX Laboratories Q3 2025 Earnings Release (November 2025).
- IDEXX Investor Day 2025 Presentation (August 2025).
- Macrotrends historical revenue and margin data for IDEXX Laboratories.
- Investing.com historical gross profit margin data for IDXX.
Do more with the Idexx Laboratories model
Frequently asked
What is Idexx Laboratories' core business model?+
Idexx Laboratories operates a classic "razor and razorblade" business model, placing diagnostic instruments in veterinary clinics. This strategy drives highly profitable, recurring revenue from consumable sales and reference laboratory testing.
What are the main revenue drivers for Idexx Laboratories?+
The primary revenue driver for Idexx Laboratories is its Companion Animal Group (CAG), which accounts for approximately 91% of total revenue. This segment benefits from recurring diagnostic consumable sales and reference laboratory testing services.
What is the assumed revenue growth rate in Idexx Laboratories' financial model?+
The financial model for Idexx Laboratories assumes a revenue growth rate of approximately 11.05%. This growth reflects the company's dominant market share in companion animal diagnostics and its innovation-driven approach.
What is Idexx Laboratories' capital expenditure strategy?+
Idexx Laboratories typically allocates 3.5% to 5.0% of its revenue to capital expenditures, with roughly 60% dedicated to growth initiatives. These investments primarily fund the expansion of its global reference laboratory network and manufacturing capacity.
What is the purpose of a financial model for IDEXX Laboratories?+
A financial model for IDEXX Laboratories provides a comprehensive 3-statement forecast and discounted cash flow valuation. Its purpose is to determine the intrinsic equity value and assess if the stock's premium valuation is justified by its recurring diagnostic revenue and margin expansion trajectory.
Is an Excel financial model available for Idexx Laboratories?+
Yes, an Excel financial model for Idexx Laboratories is available for download. This model offers a forecast horizon from FY2026 to FY2030, enabling detailed financial analysis of the company's performance.
Have more financial modelling questions? Contact us
Created by ex-finance professionals
Hey, I’m Alex and I created Finamodel.
Over my years in the finance industry I kept building the same models over and over again. Same structure, same assumptions, different logo. So I started building frameworks to turn them into clean, reusable templates.
Every model here is one I’d actually use for a client, and I personally vet each one before it goes up.
I’m not an expert in every industry, but I’ve built enough models to know what belongs in one. And when something is completely foreign to me, I reach out to my network for experts to work on our models with us.
Having a template library on hand cuts a first build from hours to minutes.
Need help finding your model? You’ll find me in the Finamodel app!
Other Medical Devices Company Financial Models
Browse another company in the same sector.
Abbott Laboratories
Abbott Laboratories is a diversified global healthcare company that discovers, develops, manufactures, and sells a broad line of healthcare products.
Align Technology
Align Technology is a global medical device company that designs, manufactures, and sells the Invisalign system of clear aligners, iTero intraoral scanners, and exocad CAD/CAM software for digital orthodontics and restorative dentistry.
Baxter International
Baxter International Inc.
Becton Dickinson
Becton, Dickinson and Company (BD) is a leading global medical technology company that develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products.
Boston Scientific
Boston Scientific is a global developer, manufacturer, and marketer of medical devices used in a broad range of interventional medical specialties.
Cooper Companies
The Cooper Companies, Inc.
Dexcom
Dexcom is a medical device company focused on the design, development, and commercialisation of continuous glucose monitoring systems that provide real-time glucose readings for people with diabetes, replacing traditional fingerstick testing.
Edwards Lifesciences
Edwards Lifesciences is a global leader in patient-focused medical innovations for structural heart disease.
Explore more Healthcare financial model templates.
